• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai March 21 Wockhardt Ltd has announced that it has got approval from the United States Food and Drug Administrator to sell its painkiller tablets that combine Dextropropoxyphene napsylate and Acetaminophen (DPN + APAP) in the US.

The approval is Wockhardt's 16th Abbreviated New Drug Application that has got regulatory clearance in the US.

The US market for the Dextropropoxyphene combination is over $100 million and is sold under the brand name Darvocet-N, a note from the company said.

Wockhardt USA Inc, a wholly-owned subsidiary of the Mumbai-based drug company, will market the painkiller in the US.

The painkiller will be made at the US FDA-certified formulation plant at Aurangabad, Maharashtra and the active ingredient in the medicine will be manufactured at its bulk drug plant at Ankleshwar, Gujarat.

The company currently markets 15 products in the US, 10 of which were launched during 2006.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
AstraZeneca global downsizing will not touch India, says CEO

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line